Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicleregeneration, but no updates on SCUBE3.
A new stem cell method for culturing hairfollicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
Microneedling at depths greater than 0.6 mm may damage miniaturized hairfollicles, with 0.5 mm showing better results for hair regrowth. Combining microneedling with minoxidil enhances absorption, but caution is advised to avoid damaging follicles.
A human trial involving verteporfin for hairregeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
Corticosterone inhibits GAS6, affecting hairfollicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hairfollicleregeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hairregeneration.
The conversation is about a hair loss treatment routine involving dermarolling, finasteride, minoxidil, and natural oils. Suggestions include using shorter needles for better absorption of treatments and longer needles less frequently for hairfollicleregeneration.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regeneratehairfollicles and sweat glands through heavy microneedling.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hairfollicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regeneratehairfollicles instead of forming scars, providing an unlimited donor supply for hair transplants.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfollicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Hair loss and its potential treatments, such as minoxidil, finasteride, RU58841, dermarolling, and supplements. It discusses whether miniaturized follicles can be revived to grow again or must shed for new growth to appear.
Verteporfin treatment shows promise for hairregeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
PP405 shows promise for reactivating hairfollicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
DHT affects hairfollicles, contributing to hair loss, but the exact mechanism is unclear. Treatments like finasteride and minoxidil are used to manage hair loss, though they may have side effects and varying effectiveness.
Japanese scientists discovered ABM cells, enabling successful human hairfollicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hairfollicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hairfollicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hairfollicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hairregeneration.
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
PP405 is a potential hair loss treatment that may activate dormant hairfollicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.